keyword
MENU ▼
Read by QxMD icon Read
search

Atomoxetine

keyword
https://www.readbyqxmd.com/read/28223809/a-review-of-the-efficacy-of-atomoxetine-in-the-treatment-of-attention-deficit-hyperactivity-disorder-in-children-and-adult-patients-with-common-comorbidities
#1
REVIEW
David B Clemow, Chris Bushe, Michele Mancini, Michael H Ossipov, Himanshu Upadhyaya
Attention-deficit hyperactivity disorder (ADHD) is a common neuropsychiatric disorder that is often diagnosed during childhood, but has also increasingly been recognized to occur in adults. Importantly, up to 52% of children (including adolescents) and 87% of adults with ADHD also have a comorbid psychiatric disorder. The presence of a comorbid disorder has the potential to impact diagnosis and could affect treatment outcomes. Atomoxetine is a nonstimulant treatment for ADHD. Despite numerous published studies regarding efficacy of atomoxetine in the treatment of ADHD in patients with comorbid disorders, there is limited information about the impact of individual common comorbid disorders on the efficacy of atomoxetine for ADHD, especially with regard to adults...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28196459/care-provision-and-prescribing-practices-of-physicians-treating-children-and-adolescents-with-adhd
#2
Ayush Patel, Rohan Medhekar, Melissa Ochoa-Perez, Rajender R Aparasu, Wenyaw Chan, Jeffrey T Sherer, Joy Alonzo, Hua Chen
OBJECTIVE: Care provision and prescribing practices of physicians treating children with attention-deficit hyperactivity disorder (ADHD) were compared. METHODS: A retrospective cohort study was conducted with the 1995-2010 General Electric Centricity Electronic Medical Record database. The sample included children (≤18 years) with newly diagnosed ADHD (ICD-9-CM code 314.XX) who received a prescription for a stimulant or atomoxetine. Identification of comorbid psychiatric disorders, duration from initial ADHD diagnosis to treatment, prescription of other psychotropic medications, and follow-up care during the ten months after the ADHD treatment initiation were compared across provider type (primary care physicians [PCPs], child psychiatrists, and physicians with an unknown specialty)...
February 15, 2017: Psychiatric Services: a Journal of the American Psychiatric Association
https://www.readbyqxmd.com/read/28195837/the-effect-of-atomoxetin-use-in-the-treatment-of-attention-deficit-hyperactivity-disorder-on-the-symptoms-of-restless-legs-syndrome-a-case-report
#3
Saliha Baykal, Melih Nuri Karakurt
Attention-deficit/hyperactivity disorder (ADHD) is frequently accompanied with sleep disorders such as obstructive sleep apnea, periodic limb movement disorder, restless legs syndrome (RLS), and circadian rhythm disorder. We have limited information about the effects of medical therapies used in the treatment of ADHD on RLS. This article discusses the effects of atomoxetine treatment on both disorders in a patient followed by diagnoses of ADHD and RLS.
February 13, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28167616/towards-trans-diagnostic-mechanisms-in-psychiatry-neurobehavioral-profile-of-rats-with-a-loss-of-function-point-mutation-in-the-dopamine-transporter-gene
#4
Valentina Vengeliene, Anton Bespalov, Martin Roßmanith, Sandra Horschitz, Stefan Berger, Ana L Relo, Hamid R Noori, Peggy Schneider, Thomas Enkel, Dusan Bartsch, Miriam Schneider, Berthold Behl, Anita C Hansson, Patrick Schloss, Rainer Spanagel
The Research Domain Criteria (RDoC) matrix has been developed to reorient psychiatric research towards measurable behavioral dimensions and underlying mechanisms. Here we used a new genetic rat model with a loss of function point mutation in the dopamine transporter (DAT) gene (Slc6a3_N157K) to systematically study the RDoC matrix (www.nimh.nih.gov/research-priorities/rdoc/constructs/rdoc-matrix.shtml). First, we examined the impact of the Slc6a3_N157K mutation on monoaminergic signaling. We then performed behavioral tests representing each of the five RDoC domains - negative and positive valence systems, cognitive, social, and in arousal/regulatory systems...
February 6, 2017: Disease Models & Mechanisms
https://www.readbyqxmd.com/read/28167075/inhibition-of-the-nmda-and-ampa-receptor-channels-by-antidepressants-and-antipsychotics
#5
Oleg I Barygin, Elina I Nagaeva, Denis B Tikhonov, Darya A Belinskaya, Nina P Vanchakova, Natalia N Shestakova
It is known that some antidepressants and antipsychotics directly inhibit NMDA-type ionotropic glutamate receptors. In this study we systematically studied action of seven drugs (Fluoxetine, Citalopram, Desipramine, Amitriptyline, Atomoxetine, Chlorpromazine, and Clozapine) on NMDA receptors and Ca(2+)-permeable and -impermeable AMPA receptors in rat brain neurons by whole-cell patch-clamp technique. Except for weak effect of fluoxetine, all drugs were virtually inactive against Ca(2+)-impermeable AMPA receptors...
February 3, 2017: Brain Research
https://www.readbyqxmd.com/read/28116581/serotonin-enhances-the-impact-of-health-information-on-food-choice
#6
Ivo Vlaev, Molly J Crockett, Luke Clark, Ulrich Müller, Trevor W Robbins
Serotonin has been implicated in promoting self-control, regulation of hunger and physiological homeostasis, and regulation of caloric intake. However, it remains unclear whether the effects of serotonin on caloric intake reflect purely homeostatic mechanisms, or whether serotonin also modulates cognitive processes involved in dietary decision making. We investigated the effects of an acute dose of the serotonin reuptake inhibitor citalopram on choices between food items that differed along taste and health attributes, compared with placebo and the noradrenaline reuptake inhibitor atomoxetine...
January 23, 2017: Cognitive, Affective & Behavioral Neuroscience
https://www.readbyqxmd.com/read/28111036/an-lc-ms-ms-method-for-the-simultaneous-determination-of-15-antipsychotics-and-two-metabolites-in-hair-and-its-application-to-rat-hair
#7
Juhyun Sim, Eunmi Kim, Wonkyung Yang, Sanghee Woo, Sangwhan In
In recent years, the inappropriate use of antipsychotics by young Korean men has become a social problem. As military service exemptions are given for mental illness, some men pose as mental health patients to avoid military service. In order to verify the authenticity of mental illnesses, we developed simultaneous analytical methods for the detection of 15 antipsychotics and 2 of their metabolites in hair using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. The target drugs were modafinil, atomoxetine, aripiprazole, benztropine, buspirone, duloxetine, gabapentin, oxcarbazepine, topiramate, escitalopram, paliperidone, ziprasidone, lamotrigine, clonazepam, levetiracetam, and metabolites of oxcarbazepine and clonazepam...
January 12, 2017: Forensic Science International
https://www.readbyqxmd.com/read/28110366/atomoxetine-treatment-for-children-and-adolescents-with-attention-deficit-hyperactivity-disorder-adhd-a-comprehensive-meta-analysis-of-outcomes-on-parent-rated-core-symptomatology
#8
REVIEW
Jessica L Gayleard, Matthew P Mychailyszyn
Attention-Deficit/Hyperactivity Disorder (ADHD) impacts a significant number of children and adolescents and often leads to deleterious functional impairment. Psychostimulant medication has historically been the first line of pharmacological intervention, though recent years have seen greater attention paid to non-stimulant alternatives. The objective of the present study was to conduct the most comprehensive meta-analysis to date evaluating the efficacy of atomoxetine in reducing core symptomatology of ADHD according to parent report...
January 21, 2017: Attention Deficit and Hyperactivity Disorders
https://www.readbyqxmd.com/read/28093662/a-cost-effectiveness-analysis-of-lisdexamfetamine-dimesylate-in-the-treatment-of-adults-with-attention-deficit-hyperactivity-disorder-in-the-uk
#9
Evelina A Zimovetz, Alain Joseph, Rajeev Ayyagari, Josephine A Mauskopf
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobehavioral disorder in children that may persist into adulthood. Lisdexamfetamine dimesylate (LDX) is approved in many countries for ADHD treatment in children, adolescents, and adults. OBJECTIVES: Estimate the cost-effectiveness of LDX as a first- or second-line treatment for adults with ADHD from the United Kingdom (UK) National Health Service (NHS) perspective compared with methylphenidate extended release (MPH-ER) and atomoxetine (ATX)...
January 16, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28092986/a-review-of-the-treatment-of-primary-orthostatic-hypotension
#10
Genevieve M Hale, Jose Valdes, Michael Brenner
OBJECTIVE: To review the efficacy and safety of pharmacological and nonpharmacological strategies used to treat primary orthostatic hypotension (OH). DATA SOURCES: A literature review using PubMed and MEDLINE databases searching hypotension, non-pharmacological therapy, midodrine, droxidopa, pyridostigmine, fludrocortisone, atomoxetine, pseudoephedrine, and octreotide was performed. STUDY SELECTION AND DATA EXTRACTION: Randomized or observational studies, cohorts, case series, or case reports written in English between January 1970 and November 2016 that assessed primary OH treatment in adult patients were evaluated...
January 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28073796/comparative-efficacy-and-tolerability-of-pharmacological-interventions-for-attention-deficit-hyperactivity-disorder-in-children-adolescents-and-adults-protocol-for-a-systematic-review-and-network-meta-analysis
#11
Samuele Cortese, Nicoletta Adamo, Christina Mohr-Jensen, Adrian J Hayes, Sahar Bhatti, Sara Carucci, Cinzia Del Giovane, Lauren Z Atkinson, Tobias Banaschewski, Emily Simonoff, Alessandro Zuddas, Corrado Barbui, Marianna Purgato, Hans-Christoph Steinhausen, Farhad Shokraneh, Jun Xia, Andrea Cipriani, David Coghill
INTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is a major public health issue. Pharmacological treatments play an important role in the multimodal treatment of ADHD. Currently, there is a lack of up-to-date and comprehensive evidence on how available ADHD drugs compare and rank in terms of efficacy and tolerability, in children or adolescents as well as in adults. We will conduct a network meta-analysis (NMA), integrating direct and indirect comparisons from randomised controlled trials (RCTs), to rank pharmacological treatments for ADHD according to their efficacy and tolerability profiles...
January 10, 2017: BMJ Open
https://www.readbyqxmd.com/read/28067776/sensitivity-of-quantitative-signal-detection-in-regards-to-pharmacological-neuroenhancement
#12
Maximilian Gahr, Bernhard J Connemann, Carlos Schönfeldt-Lecuona, René Zeiss
Pharmacological neuroenhancement (PNE) is a form of abuse and has not yet been addressed by methods of pharmacovigilance. In the present study, we tested if quantitative signal detection may be sensitive in regards to PNE. We evaluated the risk of drug abuse and dependence (DAAD) related to substances that are known to be used for PNE and divided this group into agents with (methylphenidate) and without a known abuse potential outside the field of PNE (atomoxetine, modafinil, acetylcholine esterase inhibitors, and memantine)...
January 5, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28058589/assessment-of-effects-of-atomoxetine-in-adult-patients-with-adhd-consistency-among-three-geographic-regions-in-a-response-maintenance-study
#13
Yoko Tanaka, Rodrigo Escobar, Himanshu P Upadhyaya
A previous study (Upadhyaya et al. in Eur J Psychiatry 2013b; 27:185-205) reported that adults with attention-deficit/hyperactivity disorder (ADHD) demonstrated maintenance of response for up to 25 weeks after initially responding to atomoxetine treatment. In the present report, the consistency of treatment effect across three geographic regions (Europe, United States/Canada [US/Can], and Latin America [Latin Am]) was explored. Data were analyzed from a phase 3, multicenter, randomized, double-blind, maintenance-of-response (randomized withdrawal) trial of atomoxetine versus placebo in adults with ADHD...
January 6, 2017: Attention Deficit and Hyperactivity Disorders
https://www.readbyqxmd.com/read/28052720/comparative-efficacy-and-safety-of-methylphenidate-and-atomoxetine-for-attention-deficit-hyperactivity-disorder-in-children-and-adolescents-meta-analysis-based-on-head-to-head-trials
#14
Qiang Liu, Hong Zhang, Qingqing Fang, Lili Qin
INTRODUCTION: Comparative efficacy and safety are important issues for appropriate drug selection for attention-deficit hyperactivity disorder (ADHD) treatment. Therefore we conducted a meta-analysis, where we compared atomoxetine (ATX) and methylphenidate (MPH) for ADHD treatment in children and adolescents. METHOD: Literature retrieval was conducted in relevant databases from their inception to April 2016 to select head-to-head trials that compared ATX and MPH in children and adolescents...
January 4, 2017: Journal of Clinical and Experimental Neuropsychology
https://www.readbyqxmd.com/read/27993933/pharmacological-and-non-pharmacological-treatment-of-adults-with-adhd-a-meta-review
#15
Franco De Crescenzo, Samuele Cortese, Nicoletta Adamo, Luigi Janiri
Attention-deficit/hyperactivity disorder (ADHD) is characterised by a persistent and impairing pattern of inattention and/or hyperactivity/impulsivity and it is one of the most common neuropsychiatric conditions. Evidence about interventions of adults with ADHD is growing rapidly and clinicians need a reliable summary of all the best available information in order to better inform their daily practice. We searched MEDLINE, PubMed, PsycINFO and Cochrane databases until 31 May 2016 for systematic reviews about pharmacological and non-pharmacological treatments in adults with ADHD and carried out a meta-review to address clinically relevant questions...
February 2017: Evidence-based Mental Health
https://www.readbyqxmd.com/read/27984328/sex-differences-in-the-effect-of-atomoxetine-on-the-qt-interval-in-adult-patients-with-attention-deficit-hyperactivity-disorder
#16
Yutaro Suzuki, Misuzu Tajiri, Atsunori Sugimoto, Naoki Orime, Taketsugu Hayashi, Jun Egawa, Takuro Sugai, Yoshimasa Inoue, Toshiyuki Someya
BACKGROUND: The effects of atomoxetine on QT in adults remain unclear. In this study, we examined whether the use of atomoxetine to treat attention-deficit hyperactivity disorder in adults is associated with QT prolongation. METHODS: Forty-one subjects with attention-deficit hyperactivity disorder were enrolled in this study. Participants were administered 40, 80, or 120 mg atomoxetine daily and were maintained on their respective dose for at least 2 weeks. We conducted electrocardiographic measurements and blood tests, measuring plasma atomoxetine concentrations after treatment...
February 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27973070/potential-factors-predicting-the-response-in-the-treatment-of-attention-deficit-hyperactivity-disorder-children-with-atomoxetine-in-asia-pacific-region
#17
Y Chen, Y L Zhang, X Zhang, S H Wu
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971368/a-network-meta-analysis-of-atomoxetine-methylphenidate-lisdexamfetamine-and-bupropion-for-the-treatment-of-attention-deficit-hyperactivity-disorder-in-children-and-adolescents
#18
I Locatelli, K Venišnik
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27931908/the-efficacy-of-atomoxetine-in-treating-adult-attention-deficit-hyperactivity-disorder-adhd-a-meta-analysis-of-controlled-trials
#19
Vinutha Ravishankar, Suresh Vedaveni Chowdappa, Vivek Benegal, Kesavan Muralidharan
Atomoxetine, a non-stimulant, is FDA approved drug used in the management of adult ADHD. Since the presentation of adult ADHD is different from the childhood onset condition, there is an urgent need to study the efficacy of atomoxetine on the different symptom domains of adult ADHD. To study the efficacy of atomoxetine in treating adult ADHD compared to placebo, we performed a Medline search for English language publications of Randomized Controlled Trials (RCTs) comparing atomoxetine to placebo for adult ADHD using the keywords "adult ADHD", "atomoxetine" and "placebo"...
December 2016: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/27922902/tic-symptoms-induced-by-atomoxetine-in-treatment-of-adhd-a-case-report-and-literature-review
#20
Rongwang Yang, Rong Li, Weijia Gao, Zhengyan Zhao
OBJECTIVE: Patients with attention-deficit/hyperactivity disorder (ADHD) are at increased risk for tic disorders. Atomoxetine (ATX) has been accepted as an alternative medication for patients with ADHD and a comorbid tic disorder. It is rarely reported that tic symptoms are induced by ATX. METHODS: This present report described a boy with ADHD who developed tic symptoms during ATX initiation. We used an ABAB trial to confirm the tics were related to ATX administration...
February 2017: Journal of Developmental and Behavioral Pediatrics: JDBP
keyword
keyword
4829
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"